There are two ways to manage a structural problem. The first is to intervene once the situation has already become critical. The second is to monitor weak signals, to act on trajectories before they become crises. The dominant medicine of the twentieth century was built around the first logic. This is not a criticism — it is a legitimate historical observation. For infections, trauma, and acute pathologies, this medicine has achieved extraordinary progress. But it is structurally inadequate for what now represents the leading global health burden: chronic non-communicable diseases.
This inadequacy is not an accident. It is written into the philosophy of the system itself.
Medicine 1.0, 2.0: a history of reactivity
Medicine 1.0 is empirical. Observe, associate, attempt. Hippocrates prescribing white willow bark for fever without knowing salicylic acid. Centuries of trial and error codified into practice, without any mechanistic understanding beneath the surface.
Medicine 2.0 is the era of evidence. The scientific revolution of the nineteenth century, the microbiology of Pasteur and Koch, and then the explosion of randomized controlled trials in the twentieth century radically transformed practice. Treatment is no longer given on faith in isolated observation: it relies on population data, meta-analyses, and thresholds of statistical significance. This is a fundamental advance. It eradicated epidemics, made surgery safe, and developed antibiotics and vaccines that saved hundreds of millions of lives.
But Medicine 2.0 has one major structural limitation: it is reactive by design.
Its diagnostic architecture rests on thresholds. Your LDL cholesterol is 1.89 g/L? No dyslipidemia. It rises to 1.92 g/L? You have one. The patient shifts category; a treatment is prescribed. What this paradigm fails to capture is that the trajectory leading from 1.89 to 1.92 g/L unfolds over years, sometimes decades, during which a lifestyle intervention could have altered the outcome. What it also fails to capture is the multiplicity of signals evolving simultaneously and interacting in non-linear ways.
Threshold medicine is medicine of the instantaneous state. It takes photographs. Biology, however, is a film.
The healthspan problem
Global life expectancy improved spectacularly throughout the twentieth century. In 1900, life expectancy at birth in France was approximately 45 years. Today it exceeds 82. This is a genuine victory.
But a question has gradually imposed itself in the epidemiological literature: are those additional years healthy years? The Global Burden of Disease Study 2021, which analyzed 371 pathologies across 204 countries, shows that the rise in life expectancy has not been matched by an equivalent rise in healthy life expectancy (HALE, or healthspan) (PubMed). The gap is widening: people live longer, but a growing share of those additional years are lived with significant functional limitation.
The final decade of life is statistically marked by progressive functional decline, often with multiple concurrent conditions. This is the period that proactive medicine aims to compress or postpone.
Some researchers call this the "marginal decade": the terminal period during which individuals accumulate limitations, lose autonomy, and experience accelerating deterioration in quality of life. The real question is not: how long will you live? It is: how many years will you live without depending on intensive care, without major functional limitation, with the cognitive and physical capacity that defines an active life?
James Fries formalized this question as early as 1980 under the concept of compression of morbidity: concentrating functional decline into the shortest possible window at the end of life (PubMed). The visualization is that of the rectangularization of the longevity curve. Instead of a gradual decline spread across 15 to 20 years, the goal is a high plateau of physical and cognitive performance, followed by a brief and late drop-off. Data from Danish twin studies confirm that this objective is biologically realistic: genetics determines only 20 to 25% of the aging trajectory, while the remaining 75 to 80% depends on modifiable factors (nutrition, sleep, physical activity, environment) (PubMed). The margin for action is substantial.
Medicine 2.0 is not equipped to exploit that margin. It manages declared disease, not the trajectory that leads there.
Medicine 3.0: a philosophy, not a tool
The emergence of a third medical logic has been documented in the scientific literature for several decades. Leroy Hood and Mauricio Flores formalized the concept of P4 medicine (Predictive, Preventive, Personalized, Participatory) in 2012, arguing that advances in systems biology would transform medicine into a "proactive" discipline (PubMed). Hood and Friend had already framed the stakes in oncology the year before, demonstrating how this paradigm shift applies to complex chronic pathologies (PubMed).
This is not a futurist promise. It is a reorientation already underway.
The distinction is as philosophical as it is technical. Medicine 2.0 asks: "Are you sick or not?" Medicine 3.0 asks: "In which direction is your biology moving, and can we alter that trajectory today?"
Rappaport and colleagues, in a recent review published in Cell Systems, articulate this tension plainly: "We wait for disease to shout. What if we listened when biology whispered?" (PubMed) Early signals differ fundamentally from late-stage biomarkers: they evolve according to the demographic, environmental, and behavioral context of each individual. Their detection requires continuous monitoring, not an annual snapshot.
The annual checkup is necessary. It is not sufficient.
Let us be clear: the annual medical visit remains useful. It detects manifest anomalies, updates vaccinations, and provides referrals to specialists. That is not in question.
The question is this: does an annual snapshot suffice to understand a biological trajectory?
No. No more than a photograph taken once a year allows one to understand the evolution of a glacier. Lipid, inflammatory, metabolic, and hormonal biomarkers fluctuate over time according to diet, sleep, stress, physical activity, and dozens of other variables. An isolated result gives a position. A series of results over time gives a velocity and a direction.
Longitudinal biomarker tracking is the subject of a growing scientific literature. Researchers have shown that biological ages derived from epigenetic markers (chemical modifications of DNA that reflect the body's actual wear) are superior predictors of health outcomes compared to chronological age (PubMed). Studies on epigenetic clocks demonstrate that longitudinal reliability of these markers is sufficient to detect intervention effects, provided measurement is repeated (PubMed). The metabolic profile of blood plasma itself has become a predictor of biological aging in humans (PubMed).
These findings converge toward one practical conclusion: the tools for proactive medicine already exist. What is missing is their systematic integration into preventive health practice.
Acting on trajectories, not crises
Medicine 3.0 does not claim to replace Medicine 2.0. Emergencies will continue to exist. Antibiotics will remain indispensable. Cardiac surgery will continue to save lives.
What it proposes is an additional layer: a preventive tier that acts before crises, monitors biological signals before they become symptoms, and personalizes recommendations not on the basis of what a population of 50 million people needs on average, but on the basis of what your individual biology, measured today and compared with yesterday, signals as an optimal or at-risk trajectory.
The paradigm shift unfolding before us is not a luxury for the worried wealthy. It is a logical response to the silent epidemic of chronic diseases, whose human and economic cost far exceeds that of the acute pathologies that twentieth-century medicine learned so brilliantly to manage.
The question is not whether this shift will happen. It is already underway, in research laboratories, in longitudinal cohorts, in the predictive models that computational biology makes more powerful every year. The real question is: how quickly will this transition reach everyday clinical practice? The tools exist. The data converge. What remains is the institutional architecture to deploy them at scale.
Frequently asked questions
References
- GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories, 1990-2021. Lancet. 2024;403(10440):2133-2161 (PubMed).
- Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol. 2012;29(6):613-24 (PubMed).
- Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8(3):184-7 (PubMed).
- Rappaport N, Schweickart A, Hood L, Price ND. We wait for disease to shout—What if we listened when biology whispered? Cell Systems. 2026;17(2):101509 (PubMed).
- Fingelkurts AA, Fingelkurts AA. Turning Back the Clock: A Retrospective Single-Blind Study on Brain Age Change in Response to Nutraceuticals Supplementation vs. Lifestyle Modifications. Brain Sci. 2023;13(3):520 (PubMed).
- Higgins-Chen AT et al. A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. Nat Aging. 2022;2(7):644-661 (PubMed).
- Johnson LC et al. The plasma metabolome as a predictor of biological aging in humans. Geroscience. 2019;41(6):895-906 (PubMed).
- Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med. 1980;303(3):130-135 (PubMed).
- Herskind AM, McGue M, Holm NV, et al. The heritability of human longevity: a population-based study of 2872 Danish twin pairs born 1870-1900. Hum Genet. 1996;97(3):319-323 (PubMed).
